Alvin Wong

Dr. Wong was named Chief Scientific Officer of Puma Biotechnology in June 2021. He joined Puma in March 2013 and in August 2017 he was appointed Senior Vice President, Clinical Science and Pharmacology. In April 2021, he assumed responsibility for Translational Biology and Biometrics, including Biostatistics, Programming and Data Management, in addition to Clinical Science/Pharmacology. Dr. Wong served as Clinical Lead of the successful FDA submissions of neratinib for the extended adjuvant treatment of patients with early stage HER2-positive breast cancer and subsequent submission of neratinib for patients with HER2-positive metastatic breast cancer. From 2007 to 2013, Dr. Wong was Senior Director of Clinical development at Proteolix, Inc. (acquired by Onyx) where he managed studies in multiple myeloma and supported the approval of Kyprolis®. Previously, he held positions in Clinical Pharmacology and Pharmacovigilance at Novacea, where he was the project leader of AQ4N and clinical pharmacology lead for oral vinorelbine and DN101, and in drug safety at Genentech, where he contributed to the successful submissions of Herceptin® for HER2-positive breast cancer, Rituxan® for patients with non-Hodgkin’s Lymphoma and Avastin® for patients with advanced colorectal cancer.

Dr. Wong earned his Doctor of Pharmacy degree from the University of California at San Francisco (UCSF). He was also a Clinical Professor at the UCSF School of Pharmacy from 1976 to 1996.